06:59:31 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-01-28 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-12 Kvartalsrapport 2024-Q2
2024-04-26 X-dag ordinarie utdelning XVIVO 0.00 SEK
2024-04-25 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-01-25 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-04-26 X-dag ordinarie utdelning XVIVO 0.00 SEK
2023-04-25 Årsstämma 2023
2023-04-24 Kvartalsrapport 2023-Q1
2023-01-26 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-13 Kvartalsrapport 2022-Q2
2022-04-27 X-dag ordinarie utdelning XVIVO 0.00 SEK
2022-04-26 Årsstämma 2022
2022-04-25 Kvartalsrapport 2022-Q1
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-13 Kvartalsrapport 2021-Q2
2021-04-23 X-dag ordinarie utdelning XVIVO 0.00 SEK
2021-04-22 Årsstämma 2021
2021-04-21 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-10-14 Extra Bolagsstämma 2020
2020-07-10 Kvartalsrapport 2020-Q2
2020-04-09 Kvartalsrapport 2020-Q1
2020-04-01 X-dag ordinarie utdelning XVIVO 0.00 SEK
2020-03-31 Årsstämma 2020
2020-01-30 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-12 Kvartalsrapport 2019-Q2
2019-04-26 X-dag ordinarie utdelning XVIVO 0.00 SEK
2019-04-25 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-08 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-04-30 X-dag ordinarie utdelning XVIVO 0.00 SEK
2018-04-27 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-09 Bokslutskommuniké 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-07-14 Kvartalsrapport 2017-Q2
2017-04-27 X-dag ordinarie utdelning XVIVO 0.00 SEK
2017-04-26 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-10 Extra Bolagsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-07-15 Kvartalsrapport 2016-Q2
2016-05-04 X-dag ordinarie utdelning XVIVO 0.00 SEK
2016-05-03 Årsstämma 2016
2016-04-26 Kvartalsrapport 2016-Q1
2016-02-04 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-04-24 X-dag ordinarie utdelning XVIVO 0.00 SEK
2015-04-23 Årsstämma 2015
2015-04-22 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-10-24 Analytiker möte 2014
2014-08-13 Kvartalsrapport 2014-Q2
2014-04-30 X-dag ordinarie utdelning XVIVO 0.00 SEK
2014-04-29 Årsstämma 2014
2014-04-23 Kvartalsrapport 2014-Q1
2014-02-07 Bokslutskommuniké 2013
2013-11-07 Analytiker möte 2013
2013-11-07 Kvartalsrapport 2013-Q3
2013-07-11 Kvartalsrapport 2013-Q2
2013-05-08 X-dag ordinarie utdelning XVIVO 0.00 SEK
2013-05-07 Årsstämma 2013
2013-04-19 Kvartalsrapport 2013-Q1
2013-02-19 Bokslutskommuniké 2012
2012-11-01 Kvartalsrapport 2012-Q3


ListaMid Cap Stockholm
Xvivo Perfusion är verksamt inom medicinteknik. Bolaget tillhandahåller lösningar för transplantation av lungor. Exempel på produkter som bolaget levererar innefattar kanyler, organförvaring samt kyllösningar. Produkterna vidaresäljs till kliniker och forskningsinstitut runtom den globala marknaden, med störst närvaro inom Norden och Europa. Bolaget kom till via en avknoppning från Vitrolife under 2012 och har sitt huvudkontor i Göteborg.
2023-12-22 09:00:00

In 2014, XVIVO introduced an innovative liver technology to the Italian market, designed for oxygenated perfusion prior to transplantation. Today, we are proud to announce that we have reached the significant milestone of 1,200 perfusions using XVIVO’s Liver Assist device in Italy. Machine perfusion allows for improved outcomes and more donated organs to be used saving numerous lives. Currently, 16 out of 22 liver transplant centers in Italy utilizes XVIVO's technology, including the major high-volume hospitals.

In recent years, Italy has seen approximately 1,400 liver transplants performed annually. About a quarter of these transplant procedures are performed with machine perfusion. In 2023 nearly 400 liver transplants will be performed using XVIVO’s Liver Assist. The technology improves patient outcomes after transplantation and allows for assessment of donor livers that historically would not have been accepted for transplantation, thereby increasing the utilization of donated organs. XVIVO's Liver Assist is being used for various types of donor livers, including those from donors who have deceased due to  circulatory death (DCD), those from elderly and overweight donors, but the technology also provides the opportunity of safely splitting a liver for transplantation into two patients.

The service concept offered by XVIVO in Italy includes management of the perfusion process using the technical expertise of a perfusionist. This has proven to be highly successful and the business model has shown consistent growth year after year.

In Italy three esteemed transplant surgeons have played a critical role in the implementation and development of liver machine perfusion.

"In 2015, at Niguarda Hospital, we were the first hospital to start transplanting organs from circulatory deceased donors with this technology to evaluate the functionality of the organs after 20 minutes of a flat electrocardiogram, which is mandatory in our country," says Prof. Luciano De Carlis, Director S.C. General and Transplant Surgery at Niguarda Hospital and President of the Italian Organ Transplant Society (SITO), Milan, Italy. “Over time we have been able to demonstrate that by using this technology we have improved both organ quality and the transplant process.”

Dr. Davide Ghinolfi, Acting Director of the Liver Surgery and Liver Transplant Unit, Pisan University Hospital, Pisa, Italy, adds: “Perfusion devices allow the use of livers with broad criteria, such as elderly donors, fatty livers, and other situations that, in the past, led to the discarding of organs. Today, we are able to recover many organs with this technology. For instance, in Pisa, a liver from a donor over one hundred years old was successfully transplanted to a patient who remains in good health after more than a year.”

These are some of the aspects that have allowed Italy to become the world's most frequent user of the Liver Assist technology. When reflecting on the future, Prof. Renato Romagnoli, Director of S.C. General Surgery 2U at the Liver Transplant Center, P.O. Molinette, Turin, Italy, states: “This technology has unexplored limits because the experiences gained from research so far have shown that it is possible to maintain, or even treat the liver for not just a few days, but even weeks. Soon, we will have the ability to use perfusion to regenerate, modify, or repair these organs, with the aim of transplanting more organs and optimizing the results.”

“Italy is today XVIVO’s largest liver perfusion market. Since the introduction in 2014, we have witnessed a steady utilization increase, year on year, with an acceleration in recent years. Our business model has been highly appreciated by customers and we are now looking into bringing it to other countries too. Today, approximately 25-30% of all transplanted livers in Italy have been perfused with XVIVO's technology, and I am confident that in the next two years, that number will reach 50%. We believe in an extended life of organs and that nobody should die waiting for a new organ,” says Christoffer Rosenblad, CEO of XVIVO.
December 22, 2023
Christoffer Rosenblad, CEO
XVIVO Perfusion AB (publ)